Search Results

There are 22257 results for: content related to: Transient atrial fibrillation after subcutaneous apomorphine bolus

  1. Oral apomorphine delivery from solid lipid nanoparticleswith different monostearate emulsifiers: Pharmacokinetic and behavioral evaluations

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 2, February 2011, Pages: 547–557, Ming-Jun Tsai, Yaw-Bin Huang, Pao-Chu Wu, Yaw-Syan Fu, Yao-Ren Kao, Jia-You Fang and Yi-Hung Tsai

    Version of Record online : 25 AUG 2010, DOI: 10.1002/jps.22285

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Version of Record online : 12 JUN 2015, DOI: 10.1002/mds.26295

  3. You have free access to this content
    A study of tolerance to apomorphine

    British Journal of Pharmacology

    Volume 117, Issue 5, March 1996, Pages: 781–786, Jean-Louis Montastruc, Marie-Elise Llau, Jean-Michel Senard, Marie-Antoinette Tran, Olivier Rascol and Paul Montastruc

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1476-5381.1996.tb15260.x

  4. Apomorphine: An underutilized therapy for Parkinson's disease

    Movement Disorders

    Volume 15, Issue 5, September 2000, Pages: 789–794, Werner Poewe and Gregor K. Wenning

    Version of Record online : 23 JAN 2001, DOI: 10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H

  5. Apomorphine test for dopaminergic responsiveness: A dose assessment study

    Movement Disorders

    Volume 8, Issue 2, 1993, Pages: 158–164, Dr. U. Bonuccelli, P. Piccini, P. Del Dotto, G. Rossi, G. U. Corsini and A. Muratorio

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870080207

  6. DA agonists - Non-Ergot derivaties: Apomorphine

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S83–S89,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5567

  7. Dopaminergic regulation of orexin neurons

    European Journal of Neuroscience

    Volume 21, Issue 11, June 2005, Pages: 2993–3001, Michael Bubser, Jim R. Fadel, Lela L. Jackson, James H. Meador-Woodruff, Deqiang Jing and Ariel Y. Deutch

    Version of Record online : 24 JUN 2005, DOI: 10.1111/j.1460-9568.2005.04121.x

  8. You have free access to this content
    Modulation of secretion by dopamine involves decreases in calcium and nicotinic currents in bovine chromaffin cells.

    The Journal of Physiology

    Volume 427, Issue 1, August 1, 1990, Pages: 495–517, J M Sontag, P Sanderson, M Klepper, D Aunis, K Takeda and M F Bader

    Version of Record online : 1 AUG 1990, DOI: 10.1113/jphysiol.1990.sp018184

  9. Ontogeny of apomorphine-induced stereotypy and its D1 and D2 receptor mediation in rats depleted of dopamine as neonates

    Developmental Psychobiology

    Volume 25, Issue 7, November 1992, Pages: 475–495, Dalia R. Abrams and Dr. John P. Bruno

    Version of Record online : 13 OCT 2004, DOI: 10.1002/dev.420250703

  10. Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 6, June 2006, Pages: 840–852, Dr. Crystal D. Obering, Dr. Jack J. Chen and Dr. David M. Swope

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.26.6.840

  11. You have free access to this content
    Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence from In Vivo Canine Models

    Basic & Clinical Pharmacology & Toxicology

    Volume 116, Issue 6, June 2015, Pages: 468–475, Yudai Watanabe, Yuji Nakamura, Xin Cao, Hiroshi Ohara, Yukiko Yamazaki, Norie Murayama, Yosuke Sugiyama, Hiroko Izumi-Nakaseko, Kentaro Ando, Hiroshi Yamazaki and Atsushi Sugiyama

    Version of Record online : 22 NOV 2014, DOI: 10.1111/bcpt.12343

  12. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease

    Movement Disorders

    Volume 11, Issue 6, November 1996, Pages: 633–638, Dr. T. van Laar, C. Neef, M. Danhof, K. I. Roon and R. A. C. Roos

    Version of Record online : 4 NOV 2004, DOI: 10.1002/mds.870110607

  13. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

    Movement Disorders

    Volume 13, Issue 5, September 1998, Pages: 782–787, Richard B. Dewey Jr, Demetrius M. Maraganore, J. Eric Ahlskog and Joseph Y. Matsumoto

    Version of Record online : 4 NOV 2004, DOI: 10.1002/mds.870130505

  14. Neurochemical correlates of behavioral sensitization following repeated apomorphine treatment: Assessment of the role of D1 dopamine receptor stimulation


    Volume 14, Issue 2, June 1993, Pages: 160–168, James K. Rowlett, Bruce A. Mattingly and Michael T. Bardo

    Version of Record online : 12 OCT 2004, DOI: 10.1002/syn.890140209

  15. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133


    Clinical Endocrinology

    Volume 4, Issue 3, May 1975, Pages: 277–285, SAMARTHJI LAL, JOSEPH B. MARTIN, CHARLES E. DE LA VEGA and HENRY G. FRIESEN

    Version of Record online : 17 MAR 2008, DOI: 10.1111/j.1365-2265.1975.tb01535.x

  17. You have free access to this content
    Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum

    British Journal of Pharmacology

    Volume 146, Issue 2, September 2005, Pages: 259–267, Kenshi Matsumoto, Masaki Yoshida, Karl-Erik Andersson and Petter Hedlund

    Version of Record online : 30 JAN 2009, DOI: 10.1038/sj.bjp.0706317

  18. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients

    Movement Disorders

    Volume 17, Issue 6, November/December 2002, Pages: 1235–1241, Alice J. Manson, Kirsten Turner and Andrew J. Lees

    Version of Record online : 23 JUL 2002, DOI: 10.1002/mds.10281

  19. Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

    Movement Disorders

    Volume 8, Issue 2, 1993, Pages: 165–170, A. J. Hughes, Susan Bishop, Birgit Kleedorfer, Nora Turjanski, W. Fernandez, A. J. Lees and G. M. Stern

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870080208

  20. You have free access to this content
    Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.

    British Journal of Clinical Pharmacology

    Volume 32, Issue 2, August 1991, Pages: 229–234, U Sabatini, O Rascol, P Celsis, G Houin, A Rascol, JP Marc-Vergnes and JL Montastruc

    Version of Record online : 26 JUL 2012, DOI: 10.1111/j.1365-2125.1991.tb03886.x